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Conventional therapy for cardiogenic shock complicating acute
myocardial infarction continues to be associated with a high
in-hospital mortality rate. Hemodynamic support with new me-
chanical devices and emergency coronary revascularization may
alter the long-term prognosis for patients with this complication.
Between July 1985 and March 1990, 68 patients presented to the
University of Michigan with acute myocardial infarction and
cardiogenic shock. Interventions performed included throm-
bolytic therapy (46%), intraaortic balloon pump counterpulsation
(70%), cardiac catheterization (86%), coronary angioplasty
(73%), emergency coronary artery bypass grafting/ventricular
septal defect repair (15%), Hemopump insertion (11 %), percuta-
neous cardiopulmonary support (4%) and ventricular assist de-
vice (3%).
Cardiogenic shock complicates acute myocardial infarction
in 2.4% to 12% of patients (1-3). Conventional therapy for
cardiogenic shock with coronary care unit monitoring and
vasopressor agents to support the blood pressure has histor-
ically been associated with an 80% to 90% mortality rate in
a large series (4,5). Intraaortic balloon pump therapy for
shock results in initial favorable clinical and hemodynamic
responses, but ultimately in most patients death is merely
delayed and the hospital mortality rate remains >80% (6-8).
In several recent nonrandomized series coronary revascu-
larization performed early in the course of cardiogenic shock
with use of coronary artery bypass grafting (9-12) or coro-
nary angioplasty (13-18) resulted in an apparent reduction in
the hospital mortality rate to <50% in selected patients with
shock. In addition, over the past decade, new devices to
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The 30-day survival rate was significantly better in patients
who had successful angioplasty of the infarct-related artery than
in patients with failed angioplasty (61% vs. 7%, P =0.002) or no
attempt at angioplasty (61 % vs. 14%, p =0.003). This difference
was maintained over the I-year follow-up period. The only clinical
variable that predicted survival was age <65 years.
The early use of the new support devices in 10 patients was
associated with death in 8 (80%), but this poor outcome may
reflect a selection bias for an especially high risk population.
Collectively, these recent data continue to suggest that emergency
revascularization with angioplasty may reduce the mortality rate,
but further study is required to define optimal utilization and
integration of new support devices.
(J Am Coil CardioI1992;19:647-53)
support the systemic circulation, such as a catheter-mounted
left ventricular assist device (19-22), percutaneous cardio-
pulmonary bypass support (23-26) and several surgically
implanted ventricular assist devices (27-33), have become
available for clinical investigation. It is possible that the new
support devices will stabilize these critically ill patients long
enough to permit significant functional recovery of the
myocardium and to accomplish coronary revascularization
such that the in-hospital mortality rate may be improved.
The present study reviews one center's experience with
the treatment of cardiogenic shock at a time when the
standard care for cardiogenic shock included the aggressive
use of coronary angioplasty and when several of the new
support devices became available.
Methods
Study patients. Our study group consisted of all patients
admitted to the University of Michigan Medical Center
between July 1985 and March 1990 who presented with or
developed cardiogenic shock during hospitalization for acute
myocardial infarction. Cardiogenic shock was defined as
1) sustained systolic blood pressure <80 mm Hg, or
<90 mm Hg if the blood pressure was supported by intrave-
nous pressor agents or intraaortic balloon pump therapy;
0735-1097/92/$5.00
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2) pulmonary capillary wedge pressure 2: 18 mm Hg or, if
not determined, left ventricular end-diastolic pressure
2:20 mm Hg; and 3) evidence of decreased tissue perfusion.
Acute myocardial infarction was defined as I) chest pain
>20 min in duration and unresponsive to sublingual nitro-
glycerin; 2) electrocardiographic (ECG) changes consistent
with acute myocardial infarction; and 3) elevation of serum
creatine kinase MB fraction elevation.
Coronary angioplasty. Nearly all patients with compli-
cated myocardial infarction treated at the University of
Michigan during the study period underwent, in addition to
fluid resuscitation and administration of intravenous vaso-
pressor agents, emergency cardiac catheterization using a
nonionic contrast medium. Left ventriculography generally
was not performed. A temporary atrioventricular sequential
pacemaker was placed for bradyarrhythmias or heart block.
Intraaortic balloon pump therapy was often initiated before
angiography. The decisions to proceed to coronary angio-
plasty and to use or not to use one of the support devices was
made by an experienced interventional cardiologist. Angio-
plasty was generally performed only on the infarct-related
artery. However, angioplasty of noninfarct arteries was
attempted in some patients with multivessel disease in an
effort to improve collateral flow if angioplasty of the infarct-
related artery was unsuccessful. Angioplasty was performed
through vascular sheaths in the femoral artery with use of
the Judkins technique. Patients were pretreated with aspirin
(325 mg) and heparin (10,000 to 15,000 U) was administered
immediately after sheath insertion. All significant stenoses in
the infarct-related artery were dilated with an appropriately
sized balloon catheter system. Angioplasty was considered
technically successful if flow in the infarct-related artery was
Thrombolysis in Myocardial Infarction (TIMI) grade 2 or 3
(34). After angioplasty, the patient was monitored in the
coronary care unit and treated with intravenous heparin
(adjusted to keep the partial thromboplastin time 1.5 to 2
times control), aspirin (325 mg/day), a calcium channel
blocker (if tolerated) and vasopressor agents as needed.
Coronary artery bypass grafting. Cardiopulmonary by-
pass was established as the saphenous vein was being
harvested after a single two-stage venous cannula and an
aortic cannula were connected to a silicone membrane
oxygenator primed with 2,000 ml of Normosol and 150 ml of
12.5-g albumin. Packed red blood cells (1 to 3 units) were
added to the prime solution if the preoperative hematocrit
was <30%. The left ventricle was vented routinely by
introducing a sump catheter through the left superior pulmo-
nary vein. The aorta was then cross clamped. Cardioplegic
arrest was induced in all patients with warm (37°C) sub-
strate-enriched blood cardioplegic solution containing
24 mEq/liter of potassium chloride, marked hypocalcemia
and a high glucose concentration. Initial infusion was given
at a rate of 350 ml/min to arrest the heart. After arrest, the
cardioplegic flow rate was reduced to 150 mllmin and the
warm infusion was continued for a total of 5 min. Immedi-
ately after induction of warm cardioplegia, systemic cooling
to 28°C was started and the patient received an additional
250 mllmin for 3 min of nonsubstrate-enriched cold car-
dioplegic solution. Topical hypothermia with 4°C Normosol
was used.
In all patients, the first graft was placed into the artery
supplying the largest area of contracting myocardium. The
next grafts were placed into arteries supplying viable myo-
cardial regions with smaller coronary arteries. The last
artery grafted supplied the infarct region. After the distal
anastomoses, 200 ml of the cold cardioplegic solution was
instilled through the vein grafts. Reinfusion of the cold
cardioplegic solution was instilled into the aortic root every
20 min at a flow rate of 200 mllmin for 2 min. While the last
distal anastomosis was being constructed, the patient's
systemic temperature was rewarmed to 37°C. After comple-
tion of the last distal anastomosis and before release of the
aortic cross clamp, warm glutamate/aspartate-enriched
blood was given into the aorta and down the grafts for 3 min
at a flow rate of 150 mllmin. The aortic cross clamp was
removed and the heart was defibrillated if necessary. A
partial occluding clamp was applied and the proximal anas-
tomoses performed. Distal vein grafts were perfused contin-
uously until the proximal anastomoses were completed.
Extracorporeal circulation was continued for an additional
15 min after all proximal anastomoses had been completed.
The patient was then weaned from cardiopulmonary bypass
with the use of inotropic and vasodilating drugs and I: I
intraaortic balloon counterpulsation.
Hemopump. The Hemopump (Johnson and Johnson In-
terventional Systems) was inserted in the operating room
with the established technique described by Duncan et al.
(35). Briefly, a 12-mm Dacron graft was constructed on the
femoral artery and the 2lF device was advanced under
fluoroscopic guidance across the aortic valve and placed into
a stable position in the left ventricle. The Hemopump is a
motor-driven turbine that rotates at up to 27,000 rpm,
ejecting left ventricular blood in a nonpulsatile manner into
the ascending aorta at a rate up to approximately 3.5
liters/min. The Hemopump may be used as a support device
for up to 7 days.
Percutaneous cardiopulmonary support. Percutaneous
cardiopulmonary bypass support was provided with the CPS
device (C.R. Bard, Inc.). An 18F cannula was placed in the
femoral artery and a 20F cannula was placed in the femoral
vein percutaneously by modified Seldinger technique. The
arterial cannula was advanced into the descending aorta to
approximately the level of the renal arteries and the venous
cannula was advanced under fluoroscopic guidance to the
mid-right atrium. Then, heparin (30,000 U) was given and an
activated clotting time was maintained at >300 s. The
venous blood was then cycled through the pump oxygenator
and heat exchanger and pumped through the arterial cannula
at rates up to 5 liters/min. The oxygenation membrane has a
6-h lifetime, the recommended time limit for use of the
device.
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Table 1. Clinical Data for the Series of 68 Patients
Ventricular assist device. The Symbion Total Artificial
Heart (Symbion, Inc.) was used as a bridge to cardiac
transplantation in two patients. The use of the Symbion
device is reviewed elsewhere (32,36).
Statistics. All numeric results are expressed as mean
values ± SD. Categoric variables were analyzed with the
chi-square test and continuous variables were analyzed with
a t test. A p value <0.05 was considered statistically
significant; however, values from 0.05 to 0.10 were included
for completeness. Multivariate logistic regression analyses
with an alpha to enter and remove equal to 0.15 were used to
test hypotheses regarding the independent effect of variables
on the in-hospital mortality rate.
Results
Patient characteristics (Table 1). Of the 68 patients, 50%
had anterior myocardial infarction, whereas 28% had inferior
infarction and 22% had infarction of indeterminate location
(non-Q wave in 7 patients, left bundle branch block in 5,
paced rhythm in 2 and death before an ECG was obtained in
1patient). The majority of patients presented in cardiogenic
shock within 24 h of chest pain onset, but there was great
variability in time of symptom onset to shock (mean 25 ±
55 h, range 0.5 to 336 h).
The hemodynamic data for the 68 patients are as follows:
heart rate 109 ± 23 beats/min, systolic blood pressure 74 ±
9 mm Hg, right atrial pressure 16 ± 6 mm Hg, systolic
pulmonary artery pressure 44 ± 12 mm Hg, diastolic pulmo-
nary artery pressure 26 ± 9 mm Hg, pulmonary capillary
wedge pressure 26 ± 9 mm Hg and cardiac index 2 ± 0.8
liters/min per m2• The cardiac index is likely to be artificially
elevated because most patients had been treated with several
interventions before the determination of cardiac output.
Four patients had ventriculographic and oxygen saturation
step-up evidence of a ventricular septal defect and one
All values are number and (%). VSD = ventricular septal defect.
31 (46%)
20 (30%)
8 (12%)
12 (17%)
65 (95%)
48 (70%)
59 (86%)
48 (71)%
10 (15%)
7 (11%)
3 (4%)
2 (3%)
Table 2. Interventions to Achieve Reperfusion or Provide
Systemic Support in 68 Patients
patient had clinically unsuspected free wall rupture found at
autopsy as the cause of cardiogenic shock. No patient had
evidence of a flail mitral valve leaflet or primary right
ventricular infarction as the cause of the shock.
Interventions (Table 2). Thrombolytic agents were ad-
ministered to 46% of the patients (23 intravenous, 6 intra-
coronary, 2 both intravenous and intracoronary). Nearly all
patients were treated with an intravenous pressor agent
(dopamine 91%, dobutamine 45%, I-norepinephrine 26%,
amrinone 12%, epinephrine 3%). Eighty-seven percent were
taken to the cardiac catheterization laboratory, most within
the 1st 12 h of shock, although there was a very wide range
(mean 24 ± 61 h from shock to catheterization, range 0.5 to
336). On the basis of the angiographer's assessment, coro-
nary angioplasty of the infarct-related artery was attempted
in 48 (81%) of 59 patients who underwent cardiac catheter-
ization. The primary angioplasty success rate was 73% (88%
for single-vessel disease and 61% for multivessel disease, p
= 0.04). Ten patients were referred for emergency surgery
(four for ventricular septal defect, five for coronary disease
considered unsuitable for angioplasty and one for failed
angioplasty).
Table 3 summarizes the use of the new support devices.
Hemopump placement was attempted in seven patients.
Placement was unsuccessful because of atherosclerotic dis-
ease of the iliac artery in three patients, all of whom died. Of
the four patients with successful Hemopump placement, one
patient died on day 4 when the device was accidently
dislodged from the ventricle during changing of the bed
linen, one died on day 3 after suffering a massive embolic
cerebral vascular accident and two patients survived to
discharge (Hemopump in place 3 and 5 days, respectively).
While the Hemopump was in place, it delivered up to 3.5
liters of nonpulsatile flow, which was an adequate supple-
mentation to ventricular output in all patients.
Percutaneous cardiopulmonary bypass support (USCI/
Bard) was used in three patients as a bridge to other therapy.
One patient was supported until a left ventricular assist
device was implanted, one was supported until a Hemopump
was implanted and one was supported for 42 h while awaiting
Thrombolytic therapy
Tissue-type plasminogen activator
Streptokinase
Urokinase
Intravenous pressor agents
Intraaortic balloon pump
Cardiac catheterization
Coronary angioplasty
Coronary artery bypass/vSD repair
Hemopump
Percutaneous cardiopulmonary support
Ventricular assist device
58
41
38
3
9
31
17
24
59 ± II
61
50
28
22
25 ± 55 (0.5-336)
3,444 ± 2,858 (270-12,720)
Age (yr) (mean ± SD)
% male
Medical history (%)
Hypertension
Prior myocardial infarction
Angina
Coronary artery bypass surgery
Baseline medications (%)
Digoxin
Nitrates
Beta-blockers
Calcium channel blockers
Infarct location (%)
Anterior
Inferior
Indeterminate
Hours from chest pain to shock (range)
Peak creatine kinase (IV ± SD) (range)
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Table 3. New Support Device Use in 10 Patients
Pt Age (yr)1 Adjunctive Days
No. Gender Device IRA MVD PTCA Supported Outcome
33/F HP LAD Yes Yes. successful Discharged day 19. alive at 1 year
2 48/F HP ND ND No 0 Died during device placement
3 49/M HP LAD No Yes. successful 5 Discharged day 7. died of refractory
CHF
4 391M CPS RCA Yes Yes. successful 0.5 Bridge to VAD
VAD 8 Died awaiting transplantation
5 56/M CPS LM Yes Yes. successful 0.2 Bridge to HP
HP 4 Died when device dislodged
6 69/F HP LM Yes Yes, successful 0 Died when device could not be inserted
7 49/M HP LAD No Yes. successful 0 Died during device placement
8 57/F VAD LAD Yes No 2 Died of multiple organ failure
9 48/M HP LAD Yes Yes. successful 6 Embolic stroke. died
10 43/M CPS LAD No Yes, successful 2 Died awaiting neurologic recovery from
initial cardiac arrest
CHF = congestive heart failure; CPS = cardiopulmonary bypass support; F = female; HP = Hemopump;
IRA = infarct-related artery; LAD = left anterior descending coronary artery; LM = left main coronary artery; M
= male. MVD = multivessel disease; ND = not defined (patient died before angiography could be performed); Pt =
patient; PTCA = percutaneous transluminal coronary angioplasty; RCA = right coronary artery; VAD =ventricular
assist device.
100rr----------;:::==========::::;l
Figure 1. The 30-day survival rate in 68 patients. PTCA = percuta-
neous transluminal coronary angioplasty.
survived to hospital discharge. Death before 30 days oc-
curred in five of seven patients treated with the Hemopump
and in all patients treated with the percutaneous cardiopul-
monary bypass support (n = 3) or ventricular assist device
(n = 2). One of the two patients treated with the Hemopump
who lived to hospital discharge survived to 1year; the other
died of refractory left ventricular failure at 78 days.
30
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neurologic recovery after cardiac arrest to be considered for
placement of the left ventricular assist device. All three
patients died. Cardiopulmonary bypass support provided up
to 4.5 liters/min of flow and adequate tissue perfusion in all
patients.
The Symbion ventricular assist device was placed in two
patients, in the first as a bridge to transplantation and in the
second because the patient could not be weaned from
cardiopulmonary bypass after emergency coronary artery
bypass grafting. Both died of multiple organ failure before
cardiac transplantation.
Survival at 30 days and 1 year. The 30-day survival rate
was significantly better in patients with successful angio-
plasty of the infarct-related artery than in patients with failed
angioplasty (61% vs. 7%, p = 0.002) or no attempt at
angioplasty (61% vs. 14%, p = 0.003) (Fig. 1). This differ-
ence was maintained over the I-year follow-up period (Fig.
2). Patients treated with angioplasty who had single-vessel
disease had a greater likelihood than patients with multives-
sel disease of successful recanalization of the infarct-related
artery (89% vs. 59%, p = 0.03) and a better 30-day survival
rate (56% vs. 38%, p = 0.04). The only clinical variable that
predicted improved survival was age <65 years (p = 0.026).
None of the six patients treated with emergency coronary
artery bypass grafting and none of the four patients who
underwent emergency repair of a ventricular septal defect
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Figure 2. The I-year survival rate in 68 patients. PTCA = percuta-
neous transluminal coronary angioplasty.
Discussion
The principal finding of our study is that emergency
percutaneous coronary angioplasty for cardiogenic shock is
associated with a favorable short- and long-term prognosis,
which is concordant with other reports (14-19) including an
earlier one from our institution (13), Moreover, the early
experience with new support devices, such as percutaneous
cardiopulmonary bypass or a catheter-mounted left ventric-
ular assist device, has not yet demonstrated a successful
outcome,
Revascularization with coronary angioplasty. Table 4
summarizes the published studies, none randomized, of
patients with cardiogenic shock treated with angioplasty
(13-19). Because the definition of cardiogenic shock is not
uniform among the studies, direct comparison of the results
must necessarily be limited. Angioplasty has been successful
in establishing recanalization of the infarct-related artery in
54% to 100% of vessels in which it was attempted. All of the
series suggest improvement in survival in treated as com-
pared with historical control patients. Furthermore, in all
series that separately analyzed patients on the basis of
success of the angioplasty procedure, patients with failed
angioplasty have a mortality rate similar to that of historical
-- Succeuful PTCA
-- Failed PTCA
~ -- NoPTCA
\
100
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l 60
I 40::::I
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20
o
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300 400
control patients. Our data show that despite more wide-
spread use of angioplasty (the procedure was attempted in
71 %of all of our patients presenting with cardiogenic shock),
the ability to successfully restore patency to the infarct-
related artery remains high (73%). Of patients in whom
angioplasty was successful, 63% survived to hospital dis-
charge and 48% were alive at 12 months. In contrast, only
7% of patients who had an unsuccessful attempt at angio-
plasty of the infarct-related artery survived to hospital
discharge and 1 year. Consistently, patients with single-
vessel disease have had an improved outcome compared
with that of patients with multivessel disease. The latter
patients may have a lack of compensatory hyperkinesia (37),
which in this setting may be essential to sustain adequate left
ventricular function and end-organ perfusion.
DeWood et al. (11) first showed that early emergency
coronary artery bypass grafting for cardiogenic shock im-
proved survival. Several further encouraging series have
subsequently been reported (9,10,12); however, none of
these were randomized controlled series. None of our pa-
tients sent for emergency coronary artery bypass surgery in
the setting of cardiogenic shock complicating acute myocar-
dial infarction survived to hospital discharge. It is likely that
this outcome was the result of selection bias. The only
patients sent for an emergency operation at our institution
were patients who had undergone unsuccessful angioplasty,
had diffuse high grade coronary artery disease or had a
ventricular septal defect.
Support devices. Our early experience with the new
support devices has been disappointing; however, this out-
come may again reflect selection bias toward using the
devices only in patients whose condition was the most
unstable. Merhige et al. (19) found that in dogs with isch-
emia, the Hemopump-a catheter-mounted left ventricular
assist device that works on the principle of the Archimedes
screw-decreased cardiac work, decreased left ventricular
end-diastolic pressure, maintained aortic pressure and favor-
ably redistributed blood flow in the heart so that flow to the
ischemic areas was increased. Wampler et al, (20) described
the use of the device in 28 patients with cardiogenic shock
Table 4. Summary of Studies Using Coronary Angioplasty to Treat Cardiogenic Shock Complicating Acute Myocardial Infarction
Survival (%)
First Years of Pt Successful
Hospital/30 Days Long-Term
Author Enrollment No. PTCA (%) S F A Mo S F A
Meyer (14) 1981 1 100 100 100 6 100 100
Rothbaum (15) 1982-1986 18 61
Stack (16) 1984-1986 43 58 12 53
Lee (13) 1982-1985 24 54 77 18 50
Verna (17) 1986-1987 6 100 83 83 6 67 67
O'Keefe (18) 1980-1988 39 59
Kahn (37) 1987-1989 16 50
Present study 1985-1990 48 73 61 7 45 12 48 7 36
A = all patients treated with coronary angioplasty (PTCA); F = patients with failed angioplasty; Mo = months; Pt = patient; S = patients successfully treated
with angioplasty.
652 GACIOCH ET AL.
CORONARY ANGIOPLASTY IN CARDIOGENIC SHOCK
JACC Vol. 19, No.3
March I, 1992:647-53
after acute myocardial infarction or after cardiotomy and
found a I-month survival rate of 45%. We used the Hemo-
pump in seven of our patients with shock. Our results
demonstrate some of the limitations of the Hemopump,
induding 1) difficulty advancing the 21P device in a diseased
iliac artery, 2) ventricular arrhythmias due to catheter-
induced endocardial irritability, 3) potential for accidental
dislodgment, and 4) restriction to 7 days of use. The device
is also contraindicated in patients with known left ventricu-
lar thrombus or severe aortic valve disease. A recent de-
scription (39) of a modified technique for placement of the
Hemopump may increase the rate of successful placement of
the device.
Percutaneous cardiopulmonary bypass support in cardio-
genic shock complicating acute myocardial infarction was
first described by Pennington et al. (26). Their patient was
maintained on an extracorporeal membrane oxygenation
system and then weaned to a left ventricular assist device,
but subsequently died. Shawl et al. (23-25) reported on the
use of the Bard cardiopulmonary bypass support device in 10
patients with cardiogenic shock. They found that 8 of the 10
patients were able to undergo successful supported angio-
plasty of the infarct-related artery and survived to a mean
follow-up of 10 months. In our initial experience, all three
patients were stabilized hemodynamically, were well oxy-
genated with a normal acid/base status and were systemi-
cally perfused on the cardiopulmonary bypass support de-
vice. The major limitations of this device are that it is
recommended to be used only 4 to 6 h and, because it does
not directly perfuse the myocardium, continued myocardial
necrosis may occur. There is also realistic concern over the
potential ethical dilemma of an awake aware patient sup-
ported hemodynamically by the device but with no hope of
recovering enough cardiac function to survive indepen-
dently.
We treated two patients in cardiogenic shock with the
Symbion left ventricular assist device before the use of the
device was severely restricted. There are numerous surgical
reports (31,33,40) of patients successfully supported with
various ventricular assist devices, but most were postcar-
diotomy patients who could not be weaned from cardiopul-
monary bypass and not patients with acute myocardial
infarction. Adamson et al. (27) reported a 41% survival rate
in 13 patients with acute myocardial infarction and shock
and Joyce et al. (32) reported a 50% survival rate in 26
similar patients. Other reported experiences (29,30) with a
left ventricular assist device have been less successful,
although the series are small.
Conclusions. Although not confirmed with randomized
trials, emergency revascularization of the infarct-related
artery by angioplasty appears to enhance survival in patients
with cardiogenic shock complicating acute myocardial in-
farction. The patients with the greatest likelihood of success-
ful angioplasty are those <65 years of age with single-vessel
disease. The new support devices may have a role in
stabilizing the condition of these critically ill patients long
enough to allow more definite therapy and recovery of
myocardial function, but to evaluate the devices objectively,
their use must not be restricted to patients with the least
likelihood for survival. One challenge for the future will be to
define the optimal integration of coronary revascularization
and the various support devices to further favorably affect
the otherwise poor outcome in this patient group.
We thank Annette R. Gacioch for expert assistance in the preparation of the
manuscript.
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